Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
  • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
  • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
  • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
  • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
  • A61K31/4035—Isoindoles, e.g. phthalimide
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
  • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
  • A61K31/404—Indoles, e.g. pindolol
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/415—1,2-Diazoles
  • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/415—1,2-Diazoles
  • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/4164—1,3-Diazoles
  • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/4164—1,3-Diazoles
  • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/4192—1,2,3-Triazoles
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/42—Oxazoles
  • A61K31/423—Oxazoles condensed with carbocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/4245—Oxadiazoles
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/425—Thiazoles
  • A61K31/428—Thiazoles condensed with carbocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
  • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
  • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
  • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/445—Non condensed piperidines, e.g. piperocaine
  • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
  • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/47—Quinolines; Isoquinolines
  • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/47—Quinolines; Isoquinolines
  • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
  • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/4965—Non-condensed pyrazines
  • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/50—Pyridazines; Hydrogenated pyridazines
  • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
  • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
  • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
  • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
  • A61K31/5375—1,4-Oxazines, e.g. morpholine
  • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
  • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
  • A61P11/06—Antiasthmatics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/08—Antiallergic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
  • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
  • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
  • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
  • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
  • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
  • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
  • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
  • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
  • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
  • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
  • C07D471/04—Ortho-condensed systems
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
  • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
  • C07D471/08—Bridged systems
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
  • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
  • C07D487/04—Ortho-condensed systems
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
  • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
  • C07D495/04—Ortho-condensed systems
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
  • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
  • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
  • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

• This invention relates to N-[l-cyano-2-(phenyl)ethyl]-2-azabicyclo[2.2.1]heptane-3-carboxamides and their use as inhibitors of Cathepsin C, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of diseases connected with dipeptidyl peptidase I activity, e.g. respiratory diseases.
• WO2004110988 discloses peptidyl nitrile inhibitors as dipeptidyl-peptidase I (DPPI) inhibitors for the treatment of a series of diseases.
• DPPI dipeptidyl-peptidase I
• DPPI dipeptidyl-peptidase I
• Dipeptidyl-aminopeptidase I (DPPI or Cathepsin C; EC3.4.141), is a lysosomal cysteine protease capable of removing dipeptides from the amino terminus of protein substrates.
• DPPI was first discovered by Gutman and Fruton in 1948 (J. Biol. Chem 174: 851-858, 1948).
• the cDNA of the human enzyme has been described in 1995 (Paris et al.; FEBS Lett 369: 326-330, 1995).
• the DPPI protein is processed into a mature proteolytically active enzyme consisting of a heavy chain, a light chain, and a propeptide that remains associated with the active enzyme (Wolters et al.; J. Biol.
• DPPI is a 200-kD tetramer with 4 identical subunits, each composed of the 3 different polypeptide chains. DPPI is constitutively expressed in many tissues with highest levels in lung, kidney, liver and spleen ( Kominami et al.; Biol. Chem. Hoppe Seyler 373: 367-373, 1992).
• DPPI is also relatively highly expressed in neutrophils, cytotoxic lymphocytes, natural killer cells, alveolar macrophages and mast cells. Recent data from DPPI deficient mice suggest that, besides being an important enzyme in lysosomal protein degradation, DPPI also functions as the key enzyme in the activation of granule serine proteases in cytotoxic T lymphocytes and natural killer cells
• inhibitors of Cathepsin C could potentially be useful therapeutics for the treatment of neutrophil- dominated inflammatory diseases such as chronic obstructive pulmonary disease (COPD), pulmonary emphysema, asthma, multiple sclerosis, and cystic fibrosis (Guay et al.; Curr. Topics Med. Chem. 10: 708-716, 2010; Laine and Busch-Petersen; Expert Opin. Ther. Patents 20: 497-506, 2010).
• COPD chronic obstructive pulmonary disease
• pulmonary emphysema asthma
• multiple sclerosis multiple sclerosis
• cystic fibrosis cystic fibrosis
• Rheumatoid arthritis is also another chronic inflammatory disease where DPPI appears to play a role.
• Neutrophils are recruited to the site of joint inflammation and release Cathepsin G, elastase and proteinase 3, proteases which are believed to be responsible for cartilage destruction associated with rheumatoid arthritis. Indeed, DPPI deficient mice were protected against acute arthritis induced by passive transfer of monoclonal antibodies against type II collagen (Adkison et al.; J Clin. Invest. 109: 363.371, 2002).
• Cathepsin K and in general desirable pharmacokinetic properties.
• heteroatoms selected from -S-, -S(O)-, -S(0) 2 -, -O- or -N- and the ring is aromatic, optionally substituted independently from each other with one, two, three or four R 2'1 , preferably one or two R 2'1 ;
• aryl- preferably phenyl-, optionally substituted independently from each other with one, two, three or four R 2'1 , preferably one or two R 2'1 ;
• R 2 -Ci_6-alkyl R 2' 1'1 is C3_6-cycloalkyl-, phenyl-, naphthyl-, a C 5 _io-heteroaryl- or a bicyclic Cg_io-heterocyclyl-; each optionally substituted with one, two or three halogen, HO-, NC-, Ci_6-alkyl-, Ci_ 6 -alkyl-0-; or a salt thereof.
• ring is aromatic, optionally substituted independently from each other with one, two, three or four R 2'1 , preferably one or two R 2' 1 ;
• aryl- preferably phenyl-, optionally substituted independently from each other with one, two, three or four R 2'1 , preferably one or two R 2' 1 ;
• aryl-(0)C-HN- preferably phenyl-(0)C-HN-, optionally substituted independently from each other with one, two, three or four R 2'1 , preferably one or two R 2' 1 ;
• R 2' 1'1 is phenyl-, pyridinyl-, C3_6-cycloalkyl-, each optionally substituted with one, two or three halogen, HO-, NC-, Ci_ 6 -alkyl-, Ci_ 6 -alkyl-0-; or a salt thereof.
• n 0, 1, 2, 3 or 4;
• R 1 is Ci_ 4 -alkyl-, F-, HO-, Ci_ 4 -alkyl-0-, C M -alkyl-HN-, (Ci_ 4 -alkyl) 2 N-, ;
• R 2 is selected from the group consisting of halogen, Ci_6-alkyl-, C 2 _6-alkenyl-, C3_6-cycloalkyl-, C3_6-cycloalkenyl- or a ring system selected from the group consisting of
• heteroatoms selected from -S-, -S(O)-, -S(0) 2 -, -O- or -N- and the ring is aromatic, optionally substituted independently from each other with one, two, three or four R 2'1 , preferably one or two R 2'1 ;
• aryl- preferably phenyl-, optionally substituted independently from each other with one, two, three or four R 2'1 , preferably one or two R 2'1 ;
• aryl-(0)C-HN- preferably phenyl-(0)C-HN-, optionally substituted independently from each other with one, two, three or four R 2'1 , preferably one or two R 2'1 ;
• R 2' 1'1 is phenyl-, pyridinyl-, C3_6-cycloalkyl-, each optionally substituted with one, two or three halogen, HO-, NC-, Ci_ 4 -alkyl-, Ci_ 4 -alkyl-0-; or a salt thereof.
• n 0, 1, 2, 3 or 4;
• R 1 is Me-, F-, HO-, MeO-, H 2 N-;
• R 2 is selected from the group consisting of halogen, Ci_6-alkyl-, C 2 _6-alkenyl-, C3_6-cycloalkyl-, C3_6-cycloalkenyl- or a ring system selected from the group consisting of
• heteroatoms selected from -O- or -N- and the ring is aromatic, optionally substituted independently from each other with one or two R 2'1 ;
• aryl-(0)C-HN- preferably phenyl-(0)C-HN-, optionally substituted independently from each other with one or two R 2' 1 ;
• R 2 is selected from the group consisting of halogen, Ci_6-alkyl-, C 2 _6-alkenyl-, C3_6-cycloalkyl-, C3_6-cycloalkenyl- or a ring system selected from the group consisting of
• heteroatoms selected from -O- or -N- and the ring is aromatic, optionally substituted independently from each other with one or two R 2'1 ;
• R 1 is F-, HO-;
• R 2 is selected from the group consisting of halogen, Ci_4-alkyl-, C 2 _4-alkenyl-, C3_6-cycloalkyl-, C3_6-cycloalkenyl- or
• phenyl- optionally substituted with one or two residues selected independently from each other from the group consisting of NC-, F-, Me(0) 2 S-, Et(0) 2 S-, Me(0) 2 SO-, Me 2 N(0) 2 S-, MeHN(0) 2 S-;
• R 1 is F-, HO-;
• R 2 is selected from the group consisting of ethyl-, ethenyl-, i-propenyl-, 2-methyl-n-propyl-,
• phenyl- optionally substituted with one or two residues selected independently from each other from the group consisting of NC-, F-, Me(0) 2 S-, Et(0) 2 S-, Me(0) 2 SO-, Me 2 N(0) 2 S-, MeHN(0) 2 S-;
• R 2 is selected from the group consisting of ethyl-, ethenyl-, i-propenyl-, 2-methyl-n-propyl-, 2-methyl-n-l-propenyl-, cyclohexyl-, cyclohexenyl-, I-, tetrahydro-pyranyl-, 3-6-dihydro-pyranyl-, octahydro-pyrrolo[l, 2a]pyrazinyl-, hexahydro-pyrrolo[l,
• phenyl- optionally substituted with one or two residues selected independently from each other from the group consisting of NC-, F-, Me(0) 2 S-, Et(0) 2 S-, Me(0) 2 SO-, Me 2 N(0) 2 S-, MeHN(0) 2 S-;
• R 2 is selected from the roup consisting of
• R preferred meanings for R are wherein it is selected from the group consisting of H or halogen, preferably Br, I; or selected from one of the following groups consisting of:
• A2 a monocyclic C 5 . 7 -heterocyclyl-, wherein one or two carbon atoms are replaced by
• A3 a bicyclic Cg_io-heterocyclyl-, wherein one, two, three or four carbon atoms are replaced by heteroatoms selected from -S-, -S(O)-, -S(0)2-, -O- or -N- and the ring is fully or partially saturated; preferably indolyl-, indazolyl-, chinolinyl-, isochinolinyl-, isochinolonyl-, chinolonyl-, indolin-2-onyl-, isoindolin-l -onyl-, isatinyl-, benzoxazol-2-onyl-;
• pyrrolidinopyrazinonyl- pyrrolidinopyrazinyl-, tetrahydrothienopyridinyl- preferably indol-2-onyl-, isoindol-l -onyl-, benzoxazol-2-only, pyrrolidinopyrazinonyl-,
• A4 a C 5 _6-heteroaryl-, wherein one, two or three carbon atoms are replaced by heteroatoms selected from -S-, -S(O)-, -S(0)2-, -O- or -N- and the ring is aromatic; preferably a monocyclic C 5 _6-heteroaryl-, wherein one, two or three carbon atoms are replaced by heteroatoms selected from -S-, -S(O)-, -S(0)2-, -O- or -N- and the ring is aromatic;
• Ci_6-alkyl-(0)S- Ci_ 6 -alkyl-(0) 2 S-, Ci_ 6 -alkyl-(0) 2 SO-, Ci_ 6 -alkyl-0(0)C-HN(0) 2 S-,
• R 2' 1'1 preferred meanings for R 2' 1'1 are wherein it is selected from the group consisting of phenyl-, pyridinyl-, C3_6-cycloalkyl-, each optionally substituted with one, two or three halogen, HO-, NC-, Ci_6-alkyl-, Ci_6-alkyl-0-; preferred is the group Clwhich is phenyl-, optionally substituted with one, two or three halogen, HO-, NC-, Ci_6-alkyl-, Ci_6-alkyl-0-; preferred is the group C2which is pyridinyl-, optionally substituted with one, two or three halogen, HO-, NC-, Ci_6-alkyl-, Ci_6-alkyl-0-; preferred is the group C3which is C3_6-cycloalkyl-, optionally substituted with one, two or three halogen, HO-, NC-, Ci_6-alkyl-,
• substituents from group AO each optionally substituted independently from each other with one or two residues selected from the group Bl, preferably B2; wherein R 2' 1' 1 in Bl or B2 has the meaning of CI, C2 or C3.
• substituents from group Al each optionally substituted independently from each other with one or two residues selected from the group Bl, preferably B2; wherein R 2' 1' 1 in Bl or B2 has the meaning of CI, C2 or C3.
• substituents from group A2 each optionally substituted independently from each other with one or two residues selected from the group Bl, preferably B2; wherein R 2'1'1 in Bl or B2 has the meaning of CI, C2 or C3.
• substituents from group A3 each optionally substituted independently from each other with one or two residues selected from the group Bl, preferably B2; wherein R 2' 1' 1 in Bl or B2 has the meaning of CI, C2 or C3.
• substituents from group A4 each optionally substituted independently from each other with one or two residues selected from the group Bl, preferably B2; wherein R 2' 1' 1 in Bl or B2 has the meaning of CI, C2 or C3.
• substituents from group A5 each optionally substituted independently from each other with one or two residues selected from the group Bl, preferably B2; wherein R 2' 1' 1 in Bl or B2 has the meaning of CI, C2 or C3.
• substituents from group A6 each optionally substituted independently from each other with one or two residues selected from the group Bl, preferably B2; wherein R 2' 1' 1 in Bl or B2 has the meaning of CI, C2 or C3.
• Ci_6-alkyl means an alkyl group or radical having 1 to 6 carbon atoms.
• HO alkyl group or radical having 1 to 6 carbon atoms.
• aryl-Ci_3-alkyl- means an aryl group which is bound to a Ci_3-alkyl-group, the latter of which is bound to the core or to the group to which the substituent is attached.
• prevention means the management and care of an individual at risk of developing the disease prior to the clinical onset of the disease.
• the purpose of prevention is to combat the development of the disease, condition or disorder, and includes the administration of the active compounds to prevent or delay the onset of the symptoms or complications and to prevent or delay the development of related diseases, conditions or disorders. Success of said preventive treatment is reflected statistically by reduced incidence of said condition within a patient population at risk for this condition in comparison to an equivalent patient population without preventive treatment.
• treatment means therapeutic treatment of patients having already developed one or more of said conditions in manifest, acute or chronic form, including symptomatic treatment in order to relieve symptoms of the specific indication or causal treatment in order to reverse or partially reverse the condition or to delay the progression of the indication as far as this may be possible, depending on the condition and the severity thereof.
• treatment of a disease means the management and care of a patient having developed the disease, condition or disorder.
• the purpose of treatment is to combat the disease, condition or disorder.
• Treatment includes the administration of the active compounds to eliminate or control the disease, condition or disorder as well as to alleviate the symptoms or complications associated with the disease, condition or disorder.
• a given chemical formula or name shall encompass tautomers and all stereo, optical and geometrical isomers (e.g. enantiomers, diastereomers, E/Z isomers etc%) and racemates thereof as well as mixtures in different proportions of the separate enantiomers, mixtures of diastereomers, or mixtures of any of the foregoing forms where such isomers and enantiomers exist, as well as salts, including pharmaceutically acceptable salts thereof and solvates thereof such as for instance hydrates including solvates of the free compounds or solvates of a salt of the compound.
• halogen generally denotes fluorine, chlorine, bromine and iodine.
• phrases "pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, and
• pharmaceutically acceptable salts refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof.
• examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like.
• such salts include salts from ammonia, L-arginine, betaine, benethamine, benzathine, calcium hydroxide, choline, deanol, diethanolamine (2, 2'-iminobis(ethanol)), diethylamine, 2-(diethylamino)-ethanol, 2-aminoethanol, ethylenediamine, N-ethyl-glucamine, hydrabamine, lH-imidazole, lysine, magnesium hydroxide, 4-(2-hydroxyethyl)-morpholine, piperazine, potassium hydroxide, 1 -(2-hydroxyethyl)-pyrrolidine, sodium hydroxide,
• 2.2-dichloro-acetic acid adipic acid, alginic acid, ascorbic acid, L-aspartic acid, benzenesulfonic acid, benzoic acid, 2, 5-dihydroxybenzoic acid, 4-acetamido-benzoic acid, (+)-camphoric acid, (+)-camphor-10-sulfonic acid, carbonic acid, cinnamic acid, citric acid, cyclamic acid, decanoic acid, dodecylsulfuric acid, ethane- 1, 2-disulfonic acid, ethanesulfonic acid,
• 2-hydroxy-ethanesulfonic acid ethylenediaminetetraacetic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, D-glucoheptonic acid, D-gluconic acid, D-glucuronic acid, glutamic acid, glutaric acid, 2-oxo-glutaric acid, glycerophosphoric acid, glycine, glycolic acid, hexanoic acid, hippuric acid, hydrobromic acid, hydrochloric acid, isobutyric acid, DL-lactic acid, lactobionic acid, lauric acid, lysine, maleic acid, (-)-L-malic acid, malonic acid, DL-mandelic acid, methanesulfonic acid, galactaric acid, naphthalene- 1, 5-disulfonic acid, naphthalene-2-sulfonic acid, l-hydroxy-2 -naphthoic acid, nicotinic acid,
• the pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a sufficient amount of the appropriate base or acid in water or in an organic diluent like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile, or a mixture thereof.
• Salts of other acids than those mentioned above which for example are useful for purifying or isolating the compounds of the present invention e.g. trifluoro acetate salts,
• Salts of other acids than those mentioned above which for example are useful for purifying or isolating the compounds of the present invention also comprise a part of the invention.
• Ci_ n -alkyl wherein n is 4 or 6 , either alone or in combination with another radical denotes an acyclic, saturated, branched or linear hydrocarbon radical with 1 to 4 or 6 C atoms.
• Ci_6-alkyl embraces the radicals H 3 C-, H 3 C-CH 2 -, H 3 C-CH 2 -CH 2 -,
• Ci_ n -alkyl also includes that one or more hydrogen atoms can be replaced by fluorine, examples therefore are F 3 C, F 2 HC, F 2 HC-H 2 C, F 3 C-H 2 C.
• C 2 . n -alkenyl is used for a group as defined in the definition for "Ci_ n -alkyl” with at least two carbon atoms, if at least two of those carbon atoms of said group are bonded to each other by a double bond.
• C 2 . n -alkynyl is used for a group as defined in the definition for "Ci_ n -alkyl” with at least two carbon atoms, if at least two of those carbon atoms of said group are bonded to each other by a triple bond.
• C3_6-cycloalkyl either alone or in combination with another radical denotes a cyclic, saturated, unbranched hydrocarbon radical with 6 C atoms.
• C3_ 7 -cycloalkyl includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl.
• C3_6-cycloalkenyl denotes an cyclic, unsaturated but nonaromatic, unbranched hydrocarbon radical with 6 C atoms, at least two of which are bonded to each other by a double bond.
• C3_6-cycloalkenyl includes cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclopentadienyl, cyclohexenyl and cyclohexadienyl.
• aryl as used herein, either alone or in combination with another radical, denotes a carbocyclic aromatic monocyclic group containing 6 carbon atoms which may be further fused to a second 5- or 6-membered carbocyclic group which may be aromatic, saturated or unsaturated.
• Aryl includes, but is not limited to, phenyl, indanyl, indenyl, naphthyl, anthracenyl, phenanthrenyl, tetrahydronaphthyl and dihydronaphthyl.
• monocyclic C 5 monocyclic C 5 .
• monocyclic C 5 _7-heterocyclyl is intended to include all the possible isomeric forms.
• monocyclic C 5 . 7 -heterocyclyl includes the following exemplary structures which are not depicted as radicals as each form may be attached through a covalent bond to any atom so long as appropriate valences are maintained:
• C 5 _io-heteroaryl means mono- or bicyclic ring systems containing one or more heteroatoms selected from N, O or S(0) r consisting of 5 to 10 ring atoms, preferably 5 to 6 ring atoms for for mono cyclic rings or 7 to 10 ring atoms for bicyclic rings, wherein at least one of the heteroatoms is part of aromatic ring.
• C 5 .io-heteroaryl is intended to include all the possible isomeric forms.
• the term “C 5 .io-heteroaryl” includes the following exemplary structures which are not depicted as radicals as each form may be attached through a covalent bond to any atom so long as appropriate valences are maintained:
• bicyclic Cg.io-heterocyclyl means a partially saturated or unsaturated bicyclic-ring systems including aromatic ring systems containing one or more heteroatoms selected from N, O or S(0) r consisting of 8 to 10 ring atoms wherein the heteroatoms are optionally part of the aromatic ring.
• bicyclic Cg_io-heterocyclyl is intended to include all the possible isomeric forms.
• the term "bicyclic Cg.io-heterocyclyl” includes the following exemplary structures which are not depicted as radicals as each form may be attached through a covalent bond to any atom so long as appropriate valences are maintained:
• the invention also provides processes for making a compound of Formula I.
• R 1 , R 2 and n in the formulas below shall have the meaning of R 1 , R 2 and n m Formula I of the invention described herein above.
• reaction conditions and reaction times may vary depending on the particular reactants used. Unless otherwise specified, solvents, temperatures, pressures, and other reaction conditions may be readily selected by one of ordinary skill in the art. Specific procedures are provided in the Synthetic Examples section. Typically, reaction progress may be monitored by thin layer chromatography (TLC) or LC-MS, if desired, and intermediates and products may be purified by chromatography on silica gel, HPLC and/or by recrystallization.
• TLC thin layer chromatography
• LC-MS LC-MS
• intermediates and products may be purified by chromatography on silica gel, HPLC and/or by recrystallization.
• the examples which follow are illustrative and, as recognized by one skilled in the art, particular reagents or conditions could be modified as needed for individual compounds without undue experimentation. Starting materials and intermediates used, in the methods below, are either commercially available or easily prepared from commercially available materials by those skilled in the art.
• a compound of Formula V, VII and IX may be made by the method outlined in Scheme 1 :
• a compound of Formula II wherein PG represents a protecting group (e.g. teri-butoxycarbonyl), may be reacted with an aqueous ammonia solution, using standard literature procedures for the formation of an amide.
• PG represents a protecting group (e.g. teri-butoxycarbonyl)
• a base such as N-methyl-morpholine or N-ethyl-morpholine and an activating agent such as 0-(7- Azabenzotriazol-l-yl)-N, N, N', N'-tetramethyluronium hexafluorophosphate (HATU) or O- (Benzotriazol-l-yl)- N, N, N', N'-tetramethyluroniumtetrafluoroborate (TBTU).
• HATU 0-(7- Azabenzotriazol-l-yl)-N, N, N', N'-tetramethyluronium hexafluorophosphate
• O- (Benzotriazol-l-yl)- N, N, N', N'-tetramethyluroniumtetrafluoroborate (TBTU) O- (Benzotriazol-l-yl)- N, N, N', N'-tetramethyluroniumtetraflu
• Dehydration of an amide such as in a compound of Formula III or Formula IX to the corresponding nitrile of Formula IV or VII may be carried out by use of a dehydration agent such as
• reaction of a compound of Formula VII or IX, wherein A is I or Br, with a tributyl(vinyl)tin reagent in the presence of a suitable catalyst such as bis-(triphenylphosphin)- palladiumchloride, in a suitable solvent such as dimethylformamide (DMF) and if desireable in the presence of an additive such as tetraethylammonium chloride provides compounds of Formula X or XL
• reaction of a compound of Formula VII or IX, wherein A is I or Br may be reacted with an amine in the presence of a suitable catalyst such as Cu(I)I and a suitable base such as caesium carbonate and a suitable promotor such as L-proline provides a compound of Formula X or XL
• reaction of a compound of Formula VII or IX, wherein A is N 3 with an alkyne in the presence of a suitable catalyst such as copper(II)sulfate pentahydrate and a suitable reducing agent such as L-ascorbic acid in a suitable solvent such as dimethyl sulfoxide (DMSO) / water provides a compound of Formula X or XL
• Dehydration of an amide of Formula XI to the corresponding nitrile of Formula X may be carried out by use of a dehydration agent such as (methoxycarbonylsulfamoyl)triethyl ammonium hydr
• reaction of a compound of Formula V wherein A is I or Br provides a compound of Formula XII.
• a boronic acid or the corresponding boronic acid ester in a suitable solvent such as acetonitrile, in the presence of a suitable catalyst such as 1, l-bis(di-tert-butylphosphino)ferrocene palladium dichloride and a suitable base such as K 2 CO 3 provides a compound of Formula XII.
• LCMS liquid chromatography-mass spectroscopy
• Preparative RP-HPLC purification methods use anywhere from 0-100% acetonitrile or methanol in water and TFA or ammonium hydroxide as modifier.
• Step 3 Synthesis of Intermediate 1-12.3
• DCM 150 mL
• diisopropylethylamine 13.8 mL, 79.8 mmol
• HATU 11.1 g, 29.3 mmol
• Then intermediate 1-12.2 (9.5 g, 26.6 mmol), dissolved in DCM (150 mL) is added and the mixture stirred for 3h.
• the resulting mixture is washed twice with aqu. KHSCvsolution (10%), aqu.
• Example 8 Table 1 ; Example 13, Table 1 ; Example 14, Table 1 ; Example 16, Table 1 ; Example 40, Table 1 ; Example 41, Table 1 ; Example 42, Table 1 ; Example 120 - 122, Table 1 ; Example 125, Table 1 ; Example 127, Table 1 ; Example 129, Table 1 ; Example 131, Table 1 ; Example 134, Table 1 ; Example 139-140, Table 1.
• step 1 For Examples 40 - 42, 126, 128, 130, 132, 133, 135, 136, 138, table 1, the crude product of step 1 was directly treated with formic acid to remove the Boc protecting group, thus the Boc-protected coupling product was not isolated.
• Examples 52 -73, 96 -102, Table , 1 is used instead of 1-1.4 and 1, 1 '-Bis(di-tert- butylphosphino)ferrocene-palladium dichloride is used as catalyst in step 1.
• the reaction time was of 10-15min at 40 °C.
• Examples 123, 124, table 1 the appropriate boronic ester is prepared according to the synthesis of intermediate 1-3.5, but not isolated from the reaction mixture. Instead of a work-up, the reaction mixture is cooled to room temperature, 1-1.4 (1 - 1.1 eq), PdC ⁇ dppf) (0.03 - 0.1 eq) and Na 2 C0 3 or K 2 CO 3 (3.6-5 eq) are added under inert conditions to the reaction mixture and heated to 80°C. Work up as described for Method A step 1 and final transformation to examples 123, 124 as described for Method A, step 2.
• Example 4 Example 4, Table 1 ; Example 5, Table 1 ; Example 6, Table 1 ; Example 1 1 , Table 1
• Step 1 Synthesis of 1-5.8 1-5.2 (150 mg, 0.319 mmol) and Pd/C (10%, 30 mg) in methanol (10 mL) are stirred under hydrogen (50 psi) at room temperature for 2 hours. The reaction mixture is filtered and concentrated. The crude product was carried on. m/z 372 [M+H-Boc]+, rt 1.45 min, LC-MS Method c.
• Example 10 The following compounds were synthesized in similar fashion from the appropriate intermediates: Example 2, Table 1 ; Example 9, Table 1 ; Example 30, Table 1.
• Method D Synthesis of (1R, 3S, 45)-N-((5)-l-cyano-2-(4-vinylphenyl)ethyl)-2-azabicyclo[2.2.1]heptane-3- arboxamide (Example 10, Table 1)
• Step l Synthesis of 1-4.17
• Step 2 Synthesis of 1-6.1 This step is performed in accordance to the procedure reported for Method B, step 2 using the appropriate reagents. The crude product was carried on.
• Example 20 The following compounds were synthesized in similar fashion from the appropriate intermediates: Example 20, Table 1 ; Example 21, Table 1 ; Example 22, Table 1 ; Example 23, Table 1 ; Example 24, Table 1 ; Example 25, Table 1 ; Example 26, Table 1 ; Example 27, Table 1.
• Example 29 The following compounds were synthesized in similar fashion from the appropriate intermediates: Example 29, Table 1 ; Example 31, Table 1 ; Example 32, Table 1 ; Example 33, Table 1 ; Example 39, Table 1 ; Example 51, Table 1 ; Example 103, Table 1 ; Example 105 - 113, Table 1 ; Example 117, Table 1
• 1-5.16 and 1-5-21 are synthesized by replacing DCM (2 niL) with THF (5 niL) and sulfonylchloride with the appropriate isocyanate (1.2 equ.) and stirring the reaction at 50°C for 2 hours.
• 1-5.17, 1-5.18, 1-5.19 and 1-5.22 are synthesized by replacing sulfonylchloride with the appropriate acid chloride (23 mg, 0.212 mmol) and using only 0.033 mL (0.234 mmol) triethylamine.
• 1-5.20 is synthesized by converting 1-5.12 (57 mg, 0.121 mmol) in acetonitrile (5 mL) with 2, 2- difluoroethyltrifluoromethanesulfonate (39 mg, 0.184 mmol) and using K 2 CO 3 (42 mg, 0.303 mmol) as a base.
• Example 35 Example 35, Table 1 ; Example 36, Table 1 ; Example 37, Table 1 ; Example 38, Table 1 ; Example 43, Table 1 ; Example 44, Table 1 ; Example 45, Table 1 ; Example 46, Table 1 ; Example 47, Table 1
• This step is performed in accordance to the synthesis of intermediate 1-1.4 using I-10.1and rac-(l S, 3S, 4R, 5S)-2-(tert-butoxycarbonyl)-5-fluoro-2-azabicyclo[2.2.1]heptane-3-carboxylic acid (racemic, purchased from WUXIAPPTEX) as starting materials. Boc-deprotection is performed from the crude product and in accordance with the procedure reported for method A, step 2.
• Example 75 - 95, Table 1 Example 75 - 95, Table 1 ; Example 104, Table 1
• Example 114 Table 1
• Example 115 Table 1
• Step 2 Synthesis of Example 118: 1-11.1 (180 mg, 0.361 mmol), chlorotrimethylsilane (137 ⁇ L, 1.083 mmol) and Nal (162 mg, 1.083 mmol) in acetonitrile (3 mL) are stirred at r.t. for 1.5 h. Methanol is added and the mixture is stirred at r.t. for 15 min. After evaporation of the solvents the product is isolated by HPLC. Yield: 26 %. m/z 347 [M+H]+, rt 0.28 min, LC-MS method n
• Microtiterplates (Optiplate-384 F) were purchased from PerkinElmer (Prod.No.
• the substrate Gly-Arg-AMC was from Biotrend (Prod.-No.808756 Custom peptide).
• Bovine serum albumin (BSA; Prod.No. A3059) and Dithiothreitol (DTT; Prod.No D0632) were from Sigma.
• TagZyme buffer was from Riedel-de-Haen (Prod. -No. 04269), NaCl was from Merck (Prod. -No. 1.06404.1000) and morpholinoethane sulfonic acid (MES), was from Serva (Prod. -No. 29834).
• the DPPI inhibitor Gly-Phe-DMK was purchased from MP Biomedicals (Prod.-No.03DK00625).
• the recombinant human DPPI was purchased from Prozymex. All other materials were of highest grade commercially available.
• MES buffer 25 mM MES, 50 mM NaCl, 5 mM DTT, adjusted to pH 6.0, containing 0.1% BSA
• TAGZyme Buffer 20 mM NaH 2 P0 4 , 150 mM NaCl adjusted to pH 6.0 with HC1
• Assay conditions The recombinant human DPPI was diluted in TAGZyme buffer to 1 U/ml (38.1 ⁇ g/ml, respectively), and then activated by mixing in a 1 :2 ratio with a Cysteamine aqueous solution ( 2mM) and incubating for 5 min at room temperature.
• test compound final concentration 0.1 nM to 100 ⁇
• aqua bidest containing 4% DMSO, final DMSO concentration 16%
• 10 ⁇ of DPPI in MES buffer final concentration 0.0125 ng/ ⁇
• substrate final concentration 50 ⁇
• the microtiter plates were then incubated at room temperature for 30 min. Then, the reaction was stopped by adding 10 ⁇ of Gly-Phe-DMK in MES-buffer (final concentration 1 ⁇ ).
• the fluorescence in the wells was determined using a Molecular Devices SpectraMax M5 Fluorescence Reader (Ex 360 nm, Em 460 nm) or an Envision Fluorescence Reader (Ex 355 nm, Em 460 nm).
• Each assay microtiter plate contained wells with vehicle controls (1%> DMSO in bidest + 0.075%) BSA) as reference for non- inhibited enzyme activity (100%) Ctl; high values) and wells with inhibitor (Gly-Phe-DMK, in bidest + 1% DMSO + 0.075%BSA, final concentration ⁇ ⁇ ) as controls for background fluorescence (0% Ctl; low values).
• Microtiterplates (Optiplate-384 F were purchased from PerkinElmer (Prod.No.
• the substrate Z-Gly-Pro-Arg-AMC was from Biomol (Prod. -No. P-142).
• L-Cysteine (Prod.No. 168149) was from Sigma.
• Sodium actetate was from Merck (Prod. -No. 6268.0250), EDTA was from Fluka (Prod. -No. 03680).
• the inhibitor E-64 was purchased from Sigma
• Activation buffer 32.5 mM sodium acetate, adjusted to pH 3.5 with HCl
• Assay buffer 150 mM sodium acetate, 4mM EDTA, 20 mM L-Cysteine, adjusted to pH 5.5 with HCl
• Assay conditions To activate the proenzyme, 5 ⁇ procathepsin K were mixed with lul activation buffer, and incubated at room temperature for 30 min.
• test compound final concentration 0.1 nM to 100 ⁇
• aqua bidest containing 4% DMSO, final DMSO concentration 16%
• 10 uL of Cathepsin K in assay buffer final concentration 2 ng/ ⁇
• substrate final concentration 12.5 ⁇
• the plates were then incubated at room temperature for 60min.
• the reaction was stopped by adding 10 ⁇ of E64 in assay buffer (final concentration 1 ⁇ ).
• the fluorescence in the wells was determined using a Molecular Devices SpectraMax M5 Fluorescence Reader (Ex 360 nm, Em 460 nm).
• Each assay microtiter plate contains wells with vehicle controls (1% DMSO in bidest) as reference for non- inhibited enzyme activity (100% Ctl; high values) and wells with inhibitor (E64 in bidest + 1%) DMSO, final concentration 1 ⁇ ) as controls for background fluorescence (0%> Ctl; low values).
• vehicle controls 1% DMSO in bidest
• inhibitor E64 in bidest + 1%) DMSO, final concentration 1 ⁇
• background fluorescence 0%> Ctl; low values
• the compounds of general formula I may be used on their own or combined with other active substances of formula I according to the invention.
• the compounds of general formula I may optionally also be combined with other pharmacologically active substances. These include, B2-adrenoceptor-agonists (short and long-acting), anti-cholinergics (short and long-acting), anti- inflammatory steroids (oral and topical corticosteroids), cromoglycate, methylxanthine, dissociated-glucocorticoidmimetics, PDE3 inhibitors, PDE4- inhibitors, PDE7- inhibitors, LTD4 antagonists, EGFR- inhibitors, Dopamine agonists, PAF antagonists, Lipoxin A4 derivatives, FPRLl modulators, LTB4-receptor (BLTl, BLT2) antagonists, Histamine HI receptor antagonists, Histamine H4 receptor antagonists, dual Histamine H1/H3 -receptor antagonists, PI3-kinase inhibitors,
• 5 -Lip oxygenase (5-LO) inhibitors 5 -Lip oxygenase (5-LO) inhibitors, cPLA2 inhibitors, Leukotriene A4 Hydrolase inhibitors or FLAP inhibitors, Non-steroidal anti-inflammatory agents (NSAIDs), CRTH2 antagonists, DPI -receptor modulators, Thromboxane receptor antagonists, CCR3 antagonists, CCR 4 antagonists, CCR1 antagonists, CCR5 antagonists, CCR6 antagonists, CCR7 antagonists, CCR8 antagonists, CCR9 antagonists, CCR30 antagonists, , CXCR 3 antagonists, CXCR 4 antagonists, CXCR 2 antagonists, CXCR 1 antagonists, CXCR5 antagonists, CXCR6 antagonists, CX3CR 3 antagonists, Neurokinin (NK1 , NK2) antagonists, Sphingosine 1 -Phosphate receptor modulators, Sphingosine 1 phosphate lyase inhibitors, Adeno
• A2a-agonists modulators of purinergic rezeptors as for example P2X7 inhibitors, Histone Deacetylase (HDAC) activators, Bradykinin (BK1, BK2) antagonists, TACE inhibitors, PPAR gamma modulators, Rho-kinase inhibitors, interleukin 1 -beta converting enzyme (ICE) inhibitors, Toll-Like receptor (TLR) modulators, HMG-CoA reductase inhibitors, VLA-4 antagonists, ICAM-1 inhibitors, SHIP agonists, GAB Aa receptor antagonist, ENaC-inhibitors, Prostasin- inhibitors, Matriptase-inhibitors, Melanocortin receptor (MC1R, MC2R, MC3R, MC4R, MC5R) modulators, CGRP antagonists, Endothelin antagonists, TNFa antagonists, anti-TNF antibodies, anti-GM-CSF antibodies, anti-CD46 antibodies, anti-IL
• betamimetics are betamimetics, anticholinergics, corticosteroids, PDE4-inhibitors, LTD4-antagonists, EGFR-inhibitors, CRTH2 inhibitors, 5-LO-inhibitors, Histamine receptor antagonists and SYK- inhibitors, NE-inhibitors, MMP9 inhibitors, MMP12 inhibitors, but also combinations of two or three active substances, i.e.:
• the compounds of the invention and their pharmaceutically acceptable salts have activity as pharmaceuticals, in particular as inhibitors of dipeptidyl peptidase I activity, and thus may be used in the treatment of:
• respiratory tract obstructive diseases of the airways including: asthma, including bronchial, allergic, intrinsic, extrinsic, exercise-induced, drug-induced (including aspirin and
• NSAID-induced and dust-induced asthma both intermittent and persistent and of all severities, and other causes of airway hyper-responsiveness; chronic obstructive pulmonary disease (COPD); bronchitis, including infectious and eosinophilic bronchitis; emphysema; alphal -antitrypsin deficiency, bronchiectasis; cystic fibrosis; sarcoidosis; farmer's lung and related diseases;
• COPD chronic obstructive pulmonary disease
• bronchitis including infectious and eosinophilic bronchitis; emphysema; alphal -antitrypsin deficiency, bronchiectasis; cystic fibrosis; sarcoidosis; farmer's lung and related diseases;
• lung fibrosis including cryptogenic fibrosing alveolitis, idiopathic interstitial pneumonias, fibrosis complicating anti-neoplastic therapy and chronic infection, including tuberculosis and aspergillosis and other fungal infections; complications of lung transplantation; vasculitic and thrombotic disorders of the lung vasculature, and pulmonary hypertension; antitussive activity including treatment of chronic cough associated with inflammatory and secretory conditions of the airways, and iatrogenic cough; acute and chronic rhinitis including rhinitis medicamentosa, and vasomotor rhinitis; perennial and seasonal allergic rhinitis including rhinitis nervosa (hay fever); nasal polyposis; acute viral infection including the common cold, and infection due to respiratory syncytial virus, influenza, coronavirus (including SARS) and adenovirus;
• skin psoriasis, atopic dermatitis, contact dermatitis or other eczematous dermatoses, and delayed-type hypersensitivity reactions; phyto- and photodermatitis; seborrhoeic dermatitis, dermatitis herpetiformis, lichen planus, lichen sclerosus et atrophica, pyoderma gangrenosum, skin sarcoid, discoid lupus erythematosus, pemphigus, pemphigoid, epidermolysis bullosa, urticaria, angioedema, vasculitides, toxic erythemas, cutaneous eosinophilias, alopecia areata, male-pattern baldness, Sweet's syndrome, Weber-Christian syndrome, erythema multiforme; cellulitis, both infective and non-infective; panniculitis;cutaneous lymphomas, non-melanoma
• eyes blepharitis; conjunctivitis, including perennial and vernal allergic conjunctivitis; ulceris; anterior and posterior uveitis; choroiditis; autoimmune, degenerative or inflammatory disorders affecting the retina; ophthalmitis including sympathetic ophthalmitis; sarcoidosis; infections including viral , fungal, and bacterial;
• nephritis including interstitial and glomerulonephritis; nephrotic syndrome;
• cystitis including acute and chronic (interstitial) cystitis and Hunner's ulcer; acute and chronic urethritis, prostatitis, epididymitis, oophoritis and salpingitis; vulvo-vaginitis; Peyronie's disease; erectile dysfunction (both male and female);
• allograft rejection acute and chronic following, for example, transplantation of kidney, heart, liver, lung, bone marrow, skin or cornea or following blood transfusion; or chronic graft versus host disease;
• oncology treatment of common cancers including prostate, breast, lung, ovarian, pancreatic, bowel and colon, stomach, skin and brain tumors and malignancies affecting the bone marrow (including the leukaemias) and lymphoproliferative systems, such as Hodgkin's and non-Hodgkin's lymphoma; including the prevention and treatment of metastatic disease and tumour recurrences, and paraneoplastic syndromes; and,
• infectious diseases virus diseases such as genital warts, common warts, plantar warts, hepatitis B, hepatitis C, herpes simplex virus, molluscum contagiosum, variola, human immunodeficiency virus (HIV), human papilloma virus (HPV), cytomegalovirus (CMV), varicella zoster virus (VZV), rhinovirus, adenovirus, coronavirus, influenza, para-influenza; bacterial diseases such as tuberculosis and mycobacterium avium, leprosy; other infectious diseases, such as fungal diseases, chlamydia, Candida, aspergillus, cryptococcal meningitis, Pneumocystis carnii, cryptosporidiosis, histoplasmosis, toxoplasmosis, trypanosome infection and leishmaniasis.
• virus diseases such as genital warts, common warts, plantar war
• a therapeutically effective dose will generally be in the range from about 0.01 mg to about 100 mg/kg of body weight per dosage of a compound of the invention; preferably, from about 0.1 mg to about 20 mg/kg of body weight per dosage.
• the dosage range would be from about 0.7 mg to about 7000 mg per dosage of a compound of the invention, preferably from about 7.0 mg to about 1400 mg per dosage.
• Some degree of routine dose optimization may be required to determine an optimal dosing level and pattern.
• the active ingredient may be administered from 1 to 6 times a day.
• the actual pharmaceutically effective amount or therapeutic dosage will of course depend on factors known by those skilled in the art such as age and weight of the patient, route of administration and severity of disease.
• the active ingredient will be administered at dosages and in a manner which allows a pharmaceutically effective amount to be delivered based upon patient's unique condition.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Medicinal Chemistry (AREA)
• Life Sciences & Earth Sciences (AREA)
• Epidemiology (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Pulmonology (AREA)
• Immunology (AREA)
• Rheumatology (AREA)
• Communicable Diseases (AREA)
• Orthopedic Medicine & Surgery (AREA)
• Heart & Thoracic Surgery (AREA)
• Vascular Medicine (AREA)
• Urology & Nephrology (AREA)
• Oncology (AREA)
• Pain & Pain Management (AREA)
• Hematology (AREA)
• Diabetes (AREA)
• Cardiology (AREA)
• Physical Education & Sports Medicine (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)
• Plural Heterocyclic Compounds (AREA)
• Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Indole Compounds (AREA)

Priority Applications (12)

Applications Claiming Priority (2)

Publications (1)

Family

ID=46875812

Family Applications (1)

Country Status (16)

Cited By (25)

Families Citing this family (8)

Citations (5)

Family Cites Families (2)

• 2012
  • 2012-09-14 US US13/615,781 patent/US8999975B2/en active Active
  • 2012-09-18 CN CN201280045607.0A patent/CN103814028B/zh not_active Expired - Fee Related
  • 2012-09-18 MX MX2014003080A patent/MX335941B/es unknown
  • 2012-09-18 EA EA201400358A patent/EA024817B1/ru not_active IP Right Cessation
  • 2012-09-18 JP JP2014530262A patent/JP6012736B2/ja active Active
  • 2012-09-18 KR KR1020147007194A patent/KR20140078626A/ko not_active Withdrawn
  • 2012-09-18 WO PCT/EP2012/068284 patent/WO2013041497A1/en not_active Ceased
  • 2012-09-18 AU AU2012311656A patent/AU2012311656B2/en not_active Ceased
  • 2012-09-18 EP EP12759724.3A patent/EP2758398B1/en active Active
  • 2012-09-18 PH PH1/2014/500529A patent/PH12014500529A1/en unknown
  • 2012-09-18 CA CA2848929A patent/CA2848929A1/en not_active Abandoned
  • 2012-09-18 BR BR112014006297A patent/BR112014006297A2/pt active Search and Examination
  • 2012-09-18 NZ NZ620208A patent/NZ620208A/en not_active IP Right Cessation
  • 2012-09-18 AR ARP120103441A patent/AR087913A1/es unknown
• 2014
  • 2014-02-05 IL IL230820A patent/IL230820A/en not_active IP Right Cessation
  • 2014-02-06 CL CL2014000299A patent/CL2014000299A1/es unknown

Patent Citations (5)

Non-Patent Citations (12)

Also Published As

Similar Documents

Legal Events